Safety and Efficacy of Urtica Dioica Cataplasm in the Management of Osgood-Schlatter Disease in Young Athletes

The primary objective of this clinical trial is to evaluate the efficacy and safety of a topical Urtica dioica cataplasm in managing knee pain and functional limitations in athletic children diagnosed with Osgood-Schlatter Disease. Efficacy will be assessed through changes in knee pain using the Visual Analog Scale (VAS) and functional outcomes using the Knee Injury and Osteoarthritis Outcome Score (KOOS). Three groups will be tested: * UDC Group: topical application of Urtica dioica cataplasm * Standard Care Group: oral vitamin D supplementation and physical rest * Placebo Group: topical application of a placebo cataplasm using Beta vulgaris subsp. cicla

NCT Number	NCT07096037
Lead Sponsor	Faculty of Medicine, Sousse
Conditions	Osgood-Schlatter Disease
Enrollment	90 participants
Start Date	2025-09-01
Primary Completion	2025-09-15 (estimated)
Study Completion	2026-09-30 (estimated)
Updated on ClinicalTrials.gov	2025-08-01